References
- Jacobson L O, Marks E K, Robson M D, Gaston E O, Zirkle R E. Effect of spleen protection on mortality following X-irradiation. J Lab Clin Med 1949; 34: 1538–1543
- Lorenz E, Uphoff D, Reid T R, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951; 12: 197–201
- Thomas E D, Lochte H L, Cannon J H, Sahler O D, Ferrebee J W. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 1959; 38: 1709–1716
- Storb R, Blume K G, O'Donnell M R, Chauncey T, Forman S J, Deeg H J, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transpl 2001; 7: 39–44
- Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763
- Hegenbart U, Niederwieser D, Sandmaier B M, Maris M B, Shizuru J A, Greinix H, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444–453
- Lowsky R, Takahashi T, Liu Y P, Dejbakhsh-Jones S, Grumet F C, Shizuru J A, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321–1331
- Li N, Zhao D, Zhang C, Lin C-L, Kirschbaum M, Kandeel F, et al. Histone deacetylase inhibitor SAHA reduces cytokine storm and facilitates induction of chimerism when combined with anti-CD3 mAb in conditioning of recipients. Blood (Suppl.) 2007; 2168
- Scheulen M E, Hilger R A, Oberhoff C, Casper J, Freund M, Josten K M, et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209–4216
- Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725–731
- Schmidt-Hieber M, Blau I W, Trenschel R, Andreesen R, Stuhler G, Einsele H, et al. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transpl 2007; 39: 389–396
- Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A, et al. Fludarabine and treosulfan: A novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 2007; 48: 2352–2359